Arvinas, Inc.

NasdaqGS:ARVN Stock Report

Market Cap: US$869.9m

Arvinas Management

Management criteria checks 3/4

Arvinas' CEO is Randy Teel, appointed in Feb 2026, has a tenure of less than a year. total yearly compensation is $3.78M, comprised of 12.6% salary and 87.4% bonuses, including company stock and options. directly owns 0.073% of the company’s shares, worth $638.75K. The average tenure of the management team and the board of directors is 2.2 years and 6.4 years respectively.

Key information

Randy Teel

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage12.58%
CEO tenureless than a year
CEO ownership0.07%
Management average tenure2.2yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth

Jan 27
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Nov 24

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Sep 09
Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Jun 01
We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

May 01
Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry
User avatar

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Mar 14

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Mar 12
Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Arvinas' Vepdegestrant: Why The Data May Not Hold Up

Dec 25

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Dec 24
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Nov 28
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

CEO Compensation Analysis

How has Randy Teel's remuneration changed compared to Arvinas's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$81m

Sep 30 2025n/an/a

-US$58m

Jun 30 2025n/an/a

-US$73m

Mar 31 2025n/an/a

-US$47m

Dec 31 2024US$4mUS$475k

-US$199m

Compensation vs Market: Randy's total compensation ($USD3.78M) is about average for companies of similar size in the US market ($USD3.41M).

Compensation vs Earnings: Insufficient data to compare Randy's compensation with company performance.

CEO

Randy Teel (45 yo)

less than a year
Tenure
US$3,776,333
Compensation

Dr. Randy Teel, Ph.D. served as Interim Chief Financial Officer and Treasurer at Arvinas, Inc. since February 29, 2024 until April 2024 and served as its Chief Business Officer since April 2024 until Febru...

Leadership Team

NamePositionTenureCompensationOwnership
Randy Teel
CEO, President & Directorless than a yearUS$3.78m0.073%
$ 638.7k
Andrew Saik
CFO & Treasurer1.8yrsUS$3.72m0.026%
$ 228.3k
Angela Cacace
Chief Scientific Officer1.8yrsUS$2.97m0.063%
$ 548.2k
Noah Berkowitz
Chief Medical Officer2yrsUS$6.10m0.024%
$ 208.4k
David Loomis
VP & Chief Accounting Officerno datano data0.014%
$ 125.7k
Jeff Boyle
Vice President of Investor Relations5.2yrsno datano data
Jared Freedberg
General Counsel & Corporate Secretary2.2yrsno datano data
Steve Weiss
Senior VP & Chief Human Resources Officerno datano datano data
Lisa Sinclair
Senior Vice President of Corporate Operations3.6yrsno datano data
Paul McInulty
Senior Vice President of Regulatory Affairs3.4yrsno datano data
Alexander Santini
Interim Chief Commercial Officer & Senior VP of Global and U.S. Market Accessno datano datano data
Kelly Page
Senior VP & Global Head of Oncology Strategy and Program Leadership3yrsno datano data
2.2yrs
Average Tenure
56yo
Average Age

Experienced Management: ARVN's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Randy Teel
CEO, President & Directorless than a yearUS$3.78m0.073%
$ 638.7k
Edward Kennedy
Independent Director7.7yrsUS$451.53k0.082%
$ 717.2k
Lillian Siu
Member of Scientific Advisory Board6.4yrsno datano data
Leslie Norwalk
Independent Director6.7yrsUS$451.53k0.016%
$ 136.3k
Briggs Duncan W. Morrison
Chairman & Lead Director7.8yrsUS$480.39k0.094%
$ 815.9k
Laurie Smaldone Alsup
Independent Director6.3yrsUS$456.53k0.016%
$ 136.3k
Adam Boxer
Member of Scientific Advisory Board6.4yrsno datano data
Lennart Mucke
Member of Scientific Advisory Board6.4yrsno datano data
Benjamin Neel
Member of Scientific Advisory Board6.4yrsno datano data
Linda Bain
Independent Director5.8yrsUS$461.53k0.016%
$ 136.3k
John Houston
Director8.5yrsUS$12.75m1.55%
$ 13.5m
Ian Taylor
Chairman of Scientific Advisory Board1.2yrsUS$4.22m0.18%
$ 1.6m
6.4yrs
Average Tenure
63.5yo
Average Age

Experienced Board: ARVN's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/09 19:47
End of Day Share Price 2026/03/09 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arvinas, Inc. is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBarclays
Tazeen AhmadBofA Global Research